My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Eli Lilly (NY:LLY)

1,105.00 +1104.89 (+981249.91%)

Official Closing Price Updated: 7:00 PM EDT, May 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Eli Lilly Just Got a Huge Vote of Confidence From Morgan Stanley -- and It's All About Mounjaro ↗

May 25, 2026

The efficacy of Eli Lilly's new, still-in-development GLP-1 drug is gaining attention, but don't forget its older GLP-1 drugs just yet.

Via The Motley Fool

Topics Intellectual Property

Eli Lilly Just Made a Game-Changing Move in the Billion-Dollar Weight Loss Drug Space. Here's What You Need to Know. ↗

May 25, 2026

The pharma giant is taking steps to expand its portfolio.

Via The Motley Fool

Spotting Winners: Pfizer (NYSE:PFE) And Branded Pharmaceuticals Stocks In Q1

May 24, 2026

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, incl...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Eli Lilly & Co (NYSE:LLY) Proves a Smart Pick for a Rules-Based Dividend Growth Strategy ↗

May 21, 2026

Via Chartmill

LLY: Eli Lilly & Co. Passes the Affordable Growth (GARP) Screen with Strong Momentum and Fair Valuation ↗

May 18, 2026

Via Chartmill

Better Health Care ETF: Fidelity's FHLC vs. State Street's XLV ↗

May 24, 2026

Expense ratios match, but portfolio breadth, yield, and stock concentration set these two healthcare ETFs apart for investors seeking sector exposure.

Via The Motley Fool

Topics ETFs

Is Viking Therapeutics a Top Takeover Target? ↗

May 23, 2026

Viking's strong obesity drug data continues fueling acquisition speculation.

Via The Motley Fool

MarketBeat Week in Review – 05/18 - 05/22 ↗

May 23, 2026

Stocks were up sharply to end the week as NVIDIA’s forward guidance showed tangible demand to support AI infrastructure and overshadowed mixed retail reports

Via MarketBeat

Topics Artificial Intelligence Economy

Healthcare Stocks Are on Fire -- Don't Miss These Opportunities ↗

May 22, 2026

The healthcare sector outperformed the rest of the market over the past week.

Via The Motley Fool

Topics Artificial Intelligence ETFs Economy

Eli Lilly Highlights Positive Late-Stage Foundayo Data At Obesity Conference ↗

May 22, 2026

Eli Lilly shares gained after late-stage Foundayo data showed double-digit weight loss in adults aged 65 and older across obesity trials.

Via Benzinga

Pediatrics Medicine Market Size, Industry Report By 2035 ↗

May 22, 2026

The most recent research report on the "Pediatrics Medicine Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts

Via Talk Markets

Topics Economy

3 Market-Beating Stocks with Exciting Potential

May 22, 2026

Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three ...

Via StockStory

Eli Lilly's Triple Hormone Obesity Drug Shows Significant Weight Loss ↗

May 21, 2026

Eli Lilly says retatrutide helped obesity trial participants lose up to 28.3% body weight in the Phase 3 TRIUMPH-1 study.

Via Benzinga

Eli Lilly's Next-Gen Obesity Drug Delivers Eye-Popping Weight Loss ↗

May 21, 2026

Patients lost up to 85 pounds in a study of Eli Lilly's next-generation weight-loss drug, the company said Thursday.

Via Investor's Business Daily

Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets

May 21, 2026

EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:MMA),(NYSE:NVO),(NYSE:HIMS),(NYSE:LLY) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Government

Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets

May 21, 2026

Analysts project billions in future market value as biotech innovation and consumer demand continue driving the next wave of health performance products

From MarketNewsUpdates.com

Via GlobeNewswire

Could Viking Therapeutics Be the Next Eli Lilly? ↗

May 21, 2026

Demand for weight loss drugs may fuel growth for more than one player.

Via The Motley Fool

Medicine's Not Going Anywhere: 3 of the Most Resilient Healthcare ETFs ↗

May 21, 2026

It's tough to think of an industry with more staying power than healthcare.

Via The Motley Fool

Topics ETFs Retirement

Best Weight Loss Drug Stocks to Buy in 2026 ↗

May 20, 2026

If you are looking for a GLP-1 investment, you can buy the leader, the underdog, or the upstart.

Via The Motley Fool

Topics Intellectual Property

Q1 Rundown: Elanco (NYSE:ELAN) Vs Other Pharmaceuticals Stocks

May 20, 2026

Looking back on pharmaceuticals stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Elanco (NYSE:ELAN) and its peers. The pha...

Via StockStory

Topics Artificial Intelligence Intellectual Property

From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook ↗

May 20, 2026

Eli Lilly just got more good news, posting promising results for its oral GLP-1 as the firm looks to unlock new sources of demand.

Via MarketBeat

Trump's Stock Picks Perfectly Timed With New Medicare Rules: Report ↗

May 19, 2026

Donald Trump disclosed up to $680,000 in Eli Lilly stock purchases as Medicare initiatives advanced GLP-1 drug coverage.

Via Benzinga

Topics Government

Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss Party ↗

May 18, 2026

This dark horse in the weight loss drug race is worth keeping on your watch list.

Via The Motley Fool

Eli Lilly Stock: Next Stop $2,000? ↗

May 18, 2026

The company is riding an incredible tailwind.

Via The Motley Fool

Supreme Court Rejects Eli Lilly Appeal In Medicaid Fraud Case ↗

May 18, 2026

Supreme Court lets stand $194 million Medicaid fraud award against Eli Lilly in whistleblower case challenging False Claims Act.

Via Benzinga

Topics Fraud Whistleblower

3 Deeply Undervalued Stocks You Can Buy for Less Than $100 Right Now ↗

May 18, 2026

These stocks could look like steals in a few years.

Via The Motley Fool

Topics Intellectual Property

Could Eli Lilly's Next Weight Loss Drug Waylay Wegovy -- and Even Zap Zepbound? ↗

May 17, 2026

Promising clinical trial data suggests big opportunity with Eli Lilly's retatrutide GLP-1 candidate.

Via The Motley Fool

Is Kailera Therapeutics a Buy After Its Sizzling IPO? ↗

May 16, 2026

There's a new challenger to the more established players in the weight-loss drug space.

Via The Motley Fool

Topics Initial Public Offering

If You Invested $1000 In Eli Lilly Stock 20 Years Ago, You Would Have This Much Today ↗

May 15, 2026

Via Benzinga

Buy, Sell, or Hold Novo Nordisk at $46? ↗

May 15, 2026

Can Novo Nordisk thrive under intense competitive pressures?

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.